Autopsy report · NCT00448097

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

“lack of patient population - slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

The Methodist Hospital Research Institute

Sponsor type

University, hospital or other

Conditions

Prostatic Neoplasms

Interventions

cetuximab; docetaxel

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (83% match in meaning)
• POLA+BR for Relapsed or Refractory DLBCL
  “Lack of sufficient patient population” (81% match in meaning)
• Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
  “Lack of patient population” (80% match in meaning)
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
  “Due to slow accrual of patients” (80% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.